PMID- 36858037
OWN - NLM
STAT- MEDLINE
DCOM- 20230711
LR  - 20230718
IS  - 1421-9913 (Electronic)
IS  - 0014-3022 (Linking)
VI  - 86
IP  - 3
DP  - 2023
TI  - Minor Salivary Gland Biopsy for the Diagnosis of Neurosarcoidosis.
PG  - 171-177
LID - 10.1159/000529920 [doi]
AB  - INTRODUCTION: The definite diagnosis of neurosarcoidosis is challenging since it 
      requires a compatible histology of the nervous system. When neurosarcoidosis is 
      suspected, other systemic manifestations are investigated to confirm the 
      diagnosis. A minor salivary gland biopsy (MSGB) is often performed since it is 
      minimally invasive. The objective of the present study was to assess its 
      performance for the diagnosis of neurosarcoidosis. METHODS: A retrospective 
      single-center study included patients who underwent a MSGB in a tertiary 
      neurological university hospital (Lyon, France) between 2015 and 2018. Clinical 
      presentations unlikely to be compatible with neurosarcoidosis were excluded. 
      Positive cases of neurosarcoidosis were defined as definite, probable, and 
      possible cases, according to the latest international neurosarcoidosis diagnostic 
      criteria from the Neurosarcoidosis Consortium Consensus Group. RESULTS: A total 
      of 529 patients underwent a MSGB for clinical manifestations compatible with 
      neurosarcoidosis. Among the 13 who fulfilled the criteria for neurosarcoidosis, 
      only one had a positive MSGB. The sensitivity of MSGB was 7.7% (95% CI 
      [0.2-36.0%]) and the specificity was 100.0% (95% CI [99.3-100%]). CONCLUSION: 
      Considering the low sensitivity of MSGB for the diagnosis of NS, MSGB should be 
      performed in selected indications, including a suspicion of spinal cord 
      sarcoidosis, or when there is a strong clinical, laboratory, and radiological 
      suspicion of NS. MSGB should rather not be performed when the chest CT-scan does 
      not show signs of pulmonary or lymph node sarcoidosis.
CI  - (c) 2023 The Author(s). Published by S. Karger AG, Basel.
FAU - Fournier, Nicolas
AU  - Fournier N
AD  - Hospices Civils de Lyon, Hopital de la Croix-Rousse, Service de Medecine Interne, 
      Lyon, France, nicolas.fournier@free.fr.
FAU - Jamilloux, Yvan
AU  - Jamilloux Y
AD  - Hospices Civils de Lyon, Hopital de la Croix-Rousse, Service de Medecine Interne, 
      Lyon, France.
AD  - Universite Claude Bernard Lyon-I, Research on Healthcare Performance (RESHAPE), 
      INSERM U1290, Lyon, France.
FAU - Gerfaud-Valentin, Mathieu
AU  - Gerfaud-Valentin M
AD  - Hospices Civils de Lyon, Hopital de la Croix-Rousse, Service de Medecine Interne, 
      Lyon, France.
FAU - Streichenberger, Nathalie
AU  - Streichenberger N
AD  - Hospices Civils de Lyon, Service d'Anatomie et de Cytologie Pathologiques Est, 
      Bron, France.
AD  - Universite Claude Bernard Lyon-I, Research on Healthcare Performance (RESHAPE), 
      INSERM U1290, Lyon, France.
FAU - Vukusic, Sandra
AU  - Vukusic S
AD  - Hospices Civils de Lyon, Hopital Pierre Wertheimer, Service de Neurologie - 
      Sclerose en Plaques, Pathologies de la Myeline et Neuro-Inflammation, Bron, 
      France.
AD  - Universite Claude Bernard Lyon-I, Research on Healthcare Performance (RESHAPE), 
      INSERM U1290, Lyon, France.
FAU - Marignier, Romain
AU  - Marignier R
AD  - Hospices Civils de Lyon, Hopital Pierre Wertheimer, Service de Neurologie - 
      Sclerose en Plaques, Pathologies de la Myeline et Neuro-Inflammation, Bron, 
      France.
AD  - Universite Claude Bernard Lyon-I, Research on Healthcare Performance (RESHAPE), 
      INSERM U1290, Lyon, France.
FAU - Androdias, Geraldine
AU  - Androdias G
AD  - Hospices Civils de Lyon, Hopital Pierre Wertheimer, Service de Neurologie - 
      Sclerose en Plaques, Pathologies de la Myeline et Neuro-Inflammation, Bron, 
      France.
FAU - Seve, Pascal
AU  - Seve P
AD  - Hospices Civils de Lyon, Hopital de la Croix-Rousse, Service de Medecine Interne, 
      Lyon, France.
AD  - Universite Claude Bernard Lyon-I, Research on Healthcare Performance (RESHAPE), 
      INSERM U1290, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20230301
PL  - Switzerland
TA  - Eur Neurol
JT  - European neurology
JID - 0150760
RN  - 89022-11-7 (2'-carbomethoxyphenyl 4-guanidinobenzoate)
RN  - Neurosarcoidosis
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - Salivary Glands, Minor/pathology
MH  - *Central Nervous System Diseases/diagnosis
MH  - *Sarcoidosis/diagnosis/pathology
MH  - Biopsy
OTO - NOTNLM
OT  - Minor salivary gland biopsy
OT  - Neurosarcoidosis
OT  - Sarcoidosis
EDAT- 2023/03/02 06:00
MHDA- 2023/07/11 06:42
CRDT- 2023/03/01 18:23
PHST- 2022/09/20 00:00 [received]
PHST- 2023/02/20 00:00 [accepted]
PHST- 2023/07/11 06:42 [medline]
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/01 18:23 [entrez]
AID - 000529920 [pii]
AID - 10.1159/000529920 [doi]
PST - ppublish
SO  - Eur Neurol. 2023;86(3):171-177. doi: 10.1159/000529920. Epub 2023 Mar 1.